Utilisation : Ce produit est destiné uniquement à la recherche.
Toutes les informations sur les produits présentes sur ce site sont fournies à titre éducatif uniquement. Toute forme d’introduction dans le corps humain ou animal est strictement interdite par la loi. Ce produit doit être manipulé uniquement par des professionnels agréés et qualifiés. Il ne s’agit pas d’un médicament, d’un aliment ou d’un cosmétique et il ne doit pas être présenté, utilisé ou étiqueté comme tel.
CJC-1295 without DAC 2 mg
Pendant notre changement d’emballage, vous pouvez recevoir des produits avec l’ancienne ou la nouvelle étiquette. La formulation, la pureté et la qualité restent exactement les mêmes, selon nos standards.
- Carte de crédit
- Virement bancaire (SEPA instantané)
- Virement bancaire (ACH)
- Wise
- Revolut
- Zelle
- Remitly
- Western Union
- Chime
- Autres
-25% sur tout – jusqu’au 31 octobre
25% sur les prix habituels, en remplacement des autres soldes. Cumulable uniquement avec la remise crypto.
Expédition le jour même pour les commandes aux États-Unis passées avant 12 h EST.
Voir la politique de livraison →Chaque lot est testé pour sa pureté, sa puissance et sa qualité.
Voir les résultats d’analyse →CJC-1295 without DAC is a synthetic 30-amino acid peptide analogue studied for its interactions with GHRH receptor pathways in experimental models. Also referred to as Modified GRF(1-29), the compound incorporates amino acid substitutions that confer enhanced protease resistance relative to native GHRH(1-29) while retaining GHRH receptor binding affinity.
Unlike the DAC-modified variant, CJC-1295 without DAC lacks the albumin-binding moiety, producing a shorter stability window in experimental systems that is studied for its utility in research protocols modelling pulsatile growth hormone secretagogue signalling.
Research applications include GHRH receptor pathway studies, pulsatile growth hormone signalling research, and comparative DAC versus non-DAC peptide pharmacology.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
3D Molecular Structure
Drag to rotate · scroll to zoom| Chemical Formula | C152H252N44O42 |
|---|---|
| Synonyms | Modified GRF 1-29, Mod GRF 1-29, CJC-1295 no DAC |
| Molar Mass | 3367.9 g/mol |
| CAS Number | 446262-90-4 |
| PubChem CID | 91976842 |
| Total Compound Content | 2mg per vial |
| Shelf Life | 36 months |
Results refer to the tested sample. Check the batch and date in the report.
What distinguishes CJC-1295 without DAC from CJC-1295 with DAC in GHRH research models?
CJC-1295 without DAC lacks the maleimidopropionyl-lysine Drug Affinity Complex modification present in the DAC variant, meaning it does not engage albumin-binding mechanisms that extend peptide stability in biological research systems. This results in a shorter stability window studied for its utility in experimental protocols modelling pulsatile growth hormone secretagogue signalling, which more closely approximates endogenous GHRH release patterns, in contrast to the sustained signalling profile associated with the DAC-modified variant.
Why is CJC-1295 without DAC also referred to as Modified GRF(1-29) in research literature?
CJC-1295 without DAC is structurally equivalent to Modified GRF(1-29) — a tetrasubstituted analogue of the native GHRH(1-29) sequence incorporating D-Ala2, Gln8, Ala15, and Leu27 substitutions for enhanced protease resistance. The naming distinction in research literature reflects historical convention: 'CJC-1295' strictly denotes the DAC-modified form, while 'CJC-1295 without DAC' and 'Modified GRF(1-29)' both describe the unmodified tetrasubstituted sequence without the albumin-binding moiety.
How does the single vial format compare to the 10-vial KIT format for experimental protocol planning?
The single 2mg vial is suited to pilot studies, individual experimental runs, or protocols requiring a defined single-dose quantity, while the 10-vial KIT format supports larger research programs requiring multiple independent experimental replicates or extended timelines with consistent inter-vial compound quality. Researchers select format based on the total peptide quantity needed across all experimental arms and storage requirements for unused compound.
